On Jun. 29, 2021, the National Institutes of Health announced that an adjuvant developed with its funding had contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere.

The adjuvant used in COVAXIN, Alhydroxiquim-II, was discovered and tested in the laboratory by the biotech company ViroVax of Lawrence, Kansas with support exclusively from the NIAID Adjuvant Development Program.